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OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 
75:415-421.     IF (2010)=6.378 
2. Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S and Ingelman-
Sundberg M (2010) Regulation of CYP2C19 expression by estrogen receptor alpha. 
Implications for estrogen dependent inhibition of drug metabolism. Mol Pharmacol  78:886-
94.      IF (2010)=4.725 
3. Eloranta JJ*, Wenger C*, Mwinyi J, Hiller C,Gubler C, Vavricka SR, Fried M, Kullak-Ublick 
GA, and the Swiss IBD Cohort Study Group (2011) Association of a common vitamin D-
binding protein (DBP) polymorphism with inflammatory bowel disease. Pharmacogenet 
Genomics. 2011 Sep;21(9):559-564.         IF (2010)=3.865 
4. Mwinyi J, Wenger C, Eloranta JJ and Kullak-Ublick GA (2010) Glucocorticoid receptor 
gene haplotype structure and steroid therapy outcome in IBD patients. World J 
Gastroenterol 16:3888-3896.    IF (2010)=2.092 
5. Mwinyi J*, Grete-Wenger C*, Eloranta JJ, and Kullak-Ublick GA (2011) The impact of 
PPARγ genetic variants on IBD susceptibility and IBD disease course. Accepted for 
publication in the Journal PPAR Research      IF (2010)=2.798  
 
     
	  
1.2 Three publications of high scientific value, not discussed in the “Habilitationsschrift” 
 
6. Baldwin RM*, Ohlsson S*, Pedersen RS*, Mwinyi J, Ingelman-Sundberg M, Eliasson E 
and Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 
allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767-774.  
IF (2010)=3.063 
 
7. Mwinyi J*, Nekvindova J*, Cavaco I, Hofmann Y, Pedersen RS, Landman E, Mkrtchian S 
and Ingelman-Sundberg M (2010c) New insights into the regulation of CYP2C9 gene 
expression: the role of the transcription factor GATA-4. Drug Metab Dispos 38:415-421.  
IF (2010)=3.716 
 
8.  Mwinyi J*, Cavaco I*, Yurdakok B, Mkrtchian S and Ingelman-Sundberg M (2011) The 
ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression. J 
Pharmacol Exp Ther. 2011 Jul;338(1):302-9.                        IF (2010)=4.017 
	  
	  
*   denotes equal contribution of the authors; IF = impact factor
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2. General background to the presented work and current state of research 
 
2.1 Pharmacogenetics 
Genetic variants are known to cause or contribute to human illness and to modulate patients’ 
individual responses to medical treatments, as investigated in the research field of 
pharmacogenetics. Adverse drug events (ADEs) are a major safety risk in the use of medications 
and are estimated to cause 6-7% of all hospitalizations. They impose a considerable 
pharmacoeconomic burden on the health insurance system, prolonging hospital stay by an 
average of 2 days. Many genetic variants, especially genes encoding for cytochrome P450 
enzymes or for hepatic transporters, such as in the OATP uptake transporter family have been 
shown to essentially influence the individual susceptibility for drug side effects [1]. Important 
examples include the genetic variants CYP2C9*2 and *3, which determine slow metabolism 
towards coumarin derivatives and which are connected with a significant higher risk for bleeding 
events, or CYP2D6 polymorphisms, which are able to modulate the relapse times of breast cancer 
under therapy with tamoxifen [2; 3]. These are typical examples for the often occurring scenario, 
where genetic variants directly modulate the efficacy of the drug metabolizing enzyme by inducing 
amino acid exchanges or by modulating the translation rate, introducing premature stop codons or 
splice defects into the genetic sequence. Beside this, the efficacy of drug metabolizing enzymes 
can be changed by genetic variants that occur within genes coding for transcription factors that are 
responsible for adequate gene regulation.  
 
2.2 Polymorphically expressed drug transporters and CYP enzymes: OATP1B1 and 
CYP2C19 
Liver organic anion transporting polypeptides (OATPs) are important proteins involved in the active 
uptake of drugs, xenobiotics, and amphipathic endogenous compounds from portal venous into the 
liver. They thereby initiate the hepatic first-pass metabolism and biliary elimination of a variety of 
compounds. The OATP family member OATP1B1 (coding gene: SLCO21A6) is exclusively 
expressed at the basolateral membrane of hepatocytes. OATP1B1 is known to be involved in the 
active uptake of a variety of different drugs into the liver, including 3-hydroxy-3-methylglutaryl–
coenzyme A (HMG-CoA) reductase inhibitors such as pravastatin, the antihistamine fexofenadine, 
and the angiotensin converting enzyme inhibitors enalapril and temocaprilat [4-6]. Various single 
nucleotide polymorphisms (SNPs) within SLCO1B1 have been identified by different research 
groups [7; 8]. As shown by the habilitant [9] especially 3 non-synonymous SNPs, the genetic 
variants SLCO1B1*1b, *3 and *5 occur in a high frequency within the SLCO1B1 gene and are able 
to induce a modulatory effect on the OATP1B1 drug transport efficacy and drug safety with clinical 
consequences. It could be shown that carriers of the genetic variant SLCO1B1*5 are at 
significantly higher risk to develop – partly severe - myopathies under statin therapy [10]. 
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The Cytochrome P450 family member CYP2C19 is mainly expressed in the liver [11; 12] and is 
estimated to be involved in the metabolism of approximately 5% of drugs currently used in clinical 
practice [13; 14]. Drugs, which are mainly metabolized by CYP2C19 include proton pump inhibitors 
(e.g. omeprazole, pantoprazole), diazepam, selective serotonin reuptake inhibitors (SSRI) such as 
citalopram and escitalopram, and the anti-coagulant clopidogrel [1; 15-18]. The coding gene 
CYP2C19 is highly polymorphically expressed leading to different drug metabolizer phenotypes. 
According to their enzyme activity individuals are divided into ultrafast metabolizers (homozygous 
carriers of the CYP2C19*17 allelic variant) extensive metabolizers (EM; homozygous or 
heterozygous carriers of the wild type allele) and slow metabolizers (individuals homozygous for 
the variants CYP2C19*2 or *3) with clinical consequences for therapy safety and efficacy. While 
slow metabolizers have been shown to be at higher risk for thrombotic events due to a less 
effective transformation of the prodrug clopidogrel into the antkoagulative acting metabolite  [19; 
20], while ultrafast metabolizer phenotype appears to have a protective effect against thrombotic 
occurrences [21]. 
 
2.3 The transcription factor family of Nuclear Receptors 
An important group of transcription factors displays the Nuclear Receptor family, which is involved 
in the regulation of a wide range of metabolic pathways, such as e.g. insulin sensitization of 
different tissues and lipid metabolism. Ligand-dependent activation enables them to rapidly induce 
transcription changes within the target cells. Currently, there are around 50 different nuclear 
receptors known. NRs have several characteristics in common. They are structurally composed of 
six functional regions (A–F), with are characterized by a various degree of sequence conservation. 
Most importantly, the highly conserved C region comprises the DNA-binding domain (DBD), which 
is composed of two zinc fingers, and the conserved E region, which contains the ligand-binding 
domain (LBD) [22]. Based on their ligands, NRs are can be grouped into three subfamilies: The 
first subfamily comprises the classic endocrine receptors that binds steroid and thyroid hormones 
as well as vitamine A and D derivates. The second subgroup are the so called orphan receptors 
where the ligands have not been identified yet. Members of the thris subgroup have been identified 
to bind dietary lipids and metabolizes as ligands [23]. Typically, NRs homo- or heterodimerize after 
ligand binding. The NR dimer travels from the cytoplasm into the nucleus, binds to its specific 
consensus sequence in the target gene promoters and modulates (activate or repress) gene 
expression. The recognition sites for NRs comprise typically a pair of 5 to 6 bp long DNA 
sequences (two half sites) which are often separated by a spacer of 1 to 6 bases of length. 
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2.4 Molecular biological mechanisms behind the pathogenesis of IBD 
The inflammatory bowel diseases (IBD) Crohn’s disease (CD) and ulcerative colitis (UC) are 
characterized by chronic recurrent inflammation of the gastrointestinal tract. Especially young 
people, age 20 to 40, are affected, showing a strong loss in life quality with work inability and 
repeated bowel surgeries as well as an putatively elevated risk for the development of colorectal 
cancer [24; 25]. Curative therapy strategies for IBD do not yet exist. The exact molecular 
pathogenesis of IBD is not yet fully understood. IBD is thought to be of multifactorial genesis, 
whereby environmental, microbial, immune and genetic factors seem to play an important role. 
Current evidence suggests that an initiator (commensal microorganisms within intestinal lumen or 
their by-products) in association with the disruption of the intestinal epithelium drive a dysregulated 
immune response in predisposed individuals [26]. This concept is supported by several 
observations. It could be shown that genetic polymorphisms in genes expressing pro- and anti-
inflammatory acting cytoplasmatic receptors that react on bacterial lipopolysaccharides (i.e. 
nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15 and 
NOD1/CARD4) are important susceptibility factors for development of CD [27- 30]. Current therapy 
approaches in IBD focus on a control of ongoing autoinflammatory processes within the bowel 
endothelium by using drugs that inhibit the production or the action of cytokines. This includes the 
single or combined use of steroids, 5-amino salicylic acid (5-ASA), different immunosuppressants 
(azathioprine, metothrexate) or biologicals (Anti-TNFα-antibodies (-abs)).  
The applicant has addressed the pathogenetic complexity of IBD by undertaking different research 
approaches investigating genetic factors that putatively contribute to the pathophysiology or the 
treatment outcome with immunosuppressively acting therapeutics in IBD (paper 3 to 5). Here, the 
impact of a polymorphic expression of two important nuclear receptors invovlved in 
immunmodulatory pathways, PPARγ (Peroxisome proliferator-activated receptor) and GRα 
(glucocorticoid receptor α) as well as of the cytoplasmacilly circulating Vitamine D binding protein  
(DBP), on IBD susceptibility, disease course and therapy success was studied.  
 
3. Discussion of the selected publications 
3.1 Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin 
kinetics (Paper 1) 
Hitherto, the habilitant was involved in several projects investigating the value of pharmacogenetic 
biomarkers on drug safety and efficacy in vivo. In an important clinical trial we investigated the 
influence of the often occurring genetic variants SLCO1B1*1b (rs2306283, c.388A>G) and *5 
(rs4149056, c.521T>C) on pravastatin pharmacokinetics. At the time of study performance several 
in vitro studies hinted to the fact that these OATP1B1 polymorphisms were able to modulate the 
transport efficacy of OATP1B1 in vitro [7].  Within the drug family of statins, pravastatin shows 
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unique disposition kinetics as pravastatin is not transformed by drug metabolizing enzymes and, 
thus, the extent of hepatic uptake correlates direct inversely with the abundance of the drug in the 
plasma. In the here presented in vivo trial we included 30 healthy individuals, who were either 
carriers of the alleles SLCO1B1*1b, *5 in hetero- or homozygous form or homozygous carriers of 
the wild type allele. The habilitant and her research group demonstrated that the variant c.521T>C 
is associated with significant lower OATP1B1 uptake transport capacity for pravastatin into the 
liver, which was associated with significantly higher plasma concentrations of this drug in 
SLCO1B1*5 gene variant carriers. In contrast, the carriers of the genetic variant SLCO1B1*1b 
showed lower pravastatin levels compared to wild type carriers. These novel findings were later 
repeatedly confirmed by other research groups [31; 32]  In a follow up study the habilitant and her 
research group could later show that the described pharmacokinetic effects were associated with a 
modulated lipid lowering efficacy of pravastatin. In concordance with the abundance of pravastatin 
in plasma, lipid lowering effects, as monitored by the measurement of lathosterol and cholesterol 
plasma levels, were highest in SLCO1B1*5 variant carriers, followed by wild type and 
SLCO1B1*1b carriers [33]. In a comprehensive case-control study performing a genome wide 
association analysis (GWAS) involving 300 000 candidate genes and  85 cases and 90 controls it 
was demonstrated later that the SLCO1B1 genetic polymorphism *5 dependent changes in the 
pharmacokinetics of statins are closely related to a significantly higher risk for statin induced 
myopathies [10]. Based on the repetitively confirmed association between a polymorphic 
expression of OATP1B1, pravastatin kinetics and its modulated effect on durg efficacy and safety 
[10; 34;  35] the link between the appearance of SLCO1B1 genetic variants and a modulated risk 
for statin induced myopathies is well established today. The risk modulating effect of SLCO1B1 
polymorphisms has, meanwhile, also been confirmed for other members of the statin family, such 
as e.g. simvastatin [36].  
 
3.2 Regulation of CYP2C19 expression by estrogen receptor alpha. Implications for 
estrogen dependent inhibition of drug metabolism (Paper 2) 
In several in vitro studies, the habilitant and her research group were able to shed light on the 
functional mechanisms on occurring drug-drug interactions, i.e. the putative mechanism by which 
oral contraceptives are able to inhibit the metabolism of widely used therapeutics, such as proton-
pump inhibitors or coumarin derivatives. Beside a polymorphic expression, CYP2C19 enzyme 
activity is known to be modulated by different drugs, a mechanism, which might be associated with 
a higher risk of adverse drug effects or with a failure of therapeutic efficacy of in parallel given 
CYP2C19 substrates [1; 37]. It has been repeatedly demonstrated that the intake of female sex 
steroids in the form of oral contraceptives (OC) leads to an inhibition of the metabolic efficacy 
towards CYP2C19 substrates, such as e.g. omeprazole [38; 39]. The inhibitory effect of oral 
contraceptives is not exclusively limited to CYP2C19 but has also observed with other CYP 
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enzymes, such as CYP2C9 or CYP2A6 [40;  41]. Despite the fact that, each year, approximately 
70 million women worldwide take oral contraceptives, the mechanism by which estrogens, 
especially the estradiol derivative 17α-ethinylestradiol affect CYP2C19 activity had not been have 
been clarified [42]. Estrogens exert their effects via binding to Estrogen Receptors (ERs). The 
Estrogen receptors α and β belong to the class of nuclear receptors that act as transcription factors 
upon dimerization and interaction with specific palindromically featured DNA binding sites 
(consensus sequence 5’-AGGTCAnnnTGACCT-3’) – also called estrogen responsive elements 
(EREs)  - or the respective binding half-sites within the gene promoter targets. While estrogens act 
as ER agonists, other substances are able to purely (e.g. ICI 182,780) or partially (e.g. tamoxifen 
or raloxifene) exert estrogen-antagonistic effects by binding to ERs [43; 44].  
Based on the hypothesis that an interaction between female sex steroids and CYP2C19 might 
appear due to Estrogen Receptor-dependent regulatory pathways, the habilitant and her 
colleagues investigated the ability of estradiol derivatives and the partial estrogen antagonists 
tamoxifen and raloxifene to modulate CYP2C19 gene expression. The habilitant was able to detect 
in silico an ER binding motif within the CYP2C19 gene promoter. Using important in vitro 
techniques for studying gene regulation, including cell line based co-transfection techniques and 
luciferase gene reporter assays, TaqMan® analysis, electromobility shift assays and ChIP 
analysis, the research group could demonstrate that estradiol derivates have indeed the potential 
to significantly suppress CYP2C19 expression via binding to ERα - an effect with is reversible by 
the partial ER antagonists 4-OH-tamoxifen (active metabolite of tamoxifen) or raloxifene. In a 
follow-up study the habilitant was able to show that the functionally relevant ER binding half site 
detected within CYP2C19 gene promoter appears to be conserved within other CYP2C gene 
family members, mediating also ERα dependent effects of female sex steroids on CYP2C9 gene 
expression [45]. Thus, in paper 2 the habilitant were able to deomstrate that the mechanisms of 
OC-dependent inhibition of CYP2C19 activity in vivo is likely to be mainly exerted by an inhibition 
of CYP2C19 gene transcription. The detected mechanism has putatively model character for a 
general principle, how estradiol derivatives might unfold their inhibitory potential on other members 
of the CYP enzyme family as repeatedly observed in different in vivo studies. 
  
3.3 Association of a common vitamin D-binding protein (DBP) polymorphism with 
inflammatory bowel disease (Paper 3) 
Until recently, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol), the active form of vitamin D, was 
thought to play primarily a role as one of the key regulators in calcium and phosphate metabolism, 
thereby influencing bone homeostasis. However, the observation that the vitamin D effect 
mediating protein, vitamin D receptor (VDR) is also expressed in immune cells (e.g. monocytes, 
antigen presenting cells) led to the hypothesis that vitamin D might have a more universal 
physiological function, including a regulatory role within the immune system [46;  47]. The effect of 
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vitamin D is strongly dependent on exposure to ultraviolet light, which initiates photochemical 
conversion of 7-dehydrocholesterol to cholecalciferol (vitamin D3) in the skin. In liver and kidney 
vitamin D3 is hydroxylated to the main metabolite calcitriol, whose blood concentration is well 
reflecting the overall vitamin D status of an individual.  Binding of vitamin D to VDR induces 
heterodimerization of VDR with the retinoid X receptor. The protein receptor complex subsequently 
binds to the vitamin D response elements (VDRE) within its gene promoter targets and modulates 
gene expression [48]. Interestingly, IBD is more prevalent in regions (e.g. northern Europe and 
North America) where vitamin D is less efficiently synthesized in the skin due to less exposure to 
sunlight [49; 50]. Furthermore, there is a strong correlation between the occurrence of IBD with 
malabsorption symptoms due to small-bowel resection and/ or the use of cholestyramine and 
vitamin D deficiency [51]. While is has already previously been suggested that genetic variants in 
the VDR gene are associated with IBD [52], in the work presented here our research group studied 
for the first time, whether a polymorphic expression of the human Vitamin D-binding protein (DBP) 
has an impact on IBD development. DBP, also called DBP-macrophage activating factor (DBP-
MAF), is encoded by a gene on chromosome 4. It locates in circulating plasma, where it mediates 
85% vitamin D metabolite transport to target tissues. Furthermore it is known to have many other 
important biological functions, including e.g. the mediation of bone resorption by osteoclast 
differentiation, a direct activation of osteoclasts and macrophages as well as a the mediation of 
neutrophil chemotaxis [53; 54]. There are three common isoforms of the DBP known, namely 
GC1F (wild type form), GC1S (polymorph at SNP locus rs4588 leading to the amino acid exchange 
Asp416Glu) and GC2 (polymorph at SNP locus rs7041 leading to the amino acid exchange 
Thr420Lys). In populations with European ancestry, either for SNPs rs4588 and/or rs7041, the 
allele with a lower frequency is consistently associated with lower 25(OH)D concentrations [55] In 
paper 3 we focussed on the DBP isoform determining [54] common polymorphisms rs7041 and 
rs4588 and determined their frequency in 636 IBD patients and 248 non-IBD controls. Interestingly, 
the variant Thr420Lys (isoform GC2) appeared significantly more abundant in the non-IBD control 
cohort, which would speak for a protective effect against both CD and UC. This observation is 
surprising, especially with regard to the fact that this variant has been shown to be less effective in 
vitamin D3 binding and to be associated with lower vitamin D3 plasma levels. A logical conclusion 
might be that the genetic variant Thr420Lys putatively leads to an enhanced release of vitamin D 
from DBP with subsequent protective effects of still unknown mechanism in the intestinal mucosa. 
 
3.4 Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD 
patients (Paper 4) 
Glucocorticoids (GCs) are widely used as efficient therapeutics to treat chronic inflammatory 
diseases such as rheumatoid arthritis or inflammatory bowel diseases. The drug group exerts its 
immune suppressive effects by a potent inhibition of T cell activation and cytokine secretion. This is 
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reached via a binding of Glucocorticoids to the glucocorticoid receptor (GR) and a subsequent 
promoter-dependent modulation of gene expression of different target genes, which leads e.g. to a 
transrepression of AP-1 and NF-kB signalling pathways [23; 56]. Mechanistically, steroids bind to 
the cytoplasmically located glucocorticoid receptor, which homodimerizes and translocates into the 
nucleus. Here, the protein-receptor complex subsequently targets -  together with multiple co-
regulating proteins - specific glucocorticoid response elements (GREs, 5’-GGTACAnnnTGTTCT-3’ 
where n refers to any nucleotide) within the regulatory regions of GR regulated genes and 
modulates their expression. GCs are often used in the initial treatment of most cases of moderately 
to severely active UC or CD. However, 20% of patients develop GC resistance within one year of 
treatment, leading to the need for a surgical intervention as a result of a poor therapy outcome. 
The mechanisms by which GC resistance develops are, however, not yet fully understood [57;  58]. 
Three possible mechanisms of how GC resistance develops have been proposed. First, decreased 
plasma levels of GCs through overexpression of the drug efflux system P-glycoprotein (MDR1). 
Second, an altered function of GR or, third, excessive synthesis of pro-inflammatory cytokines 
induced by activation of pro-inflammatory transcription factors may reduce the affinity of GR to its 
ligands and lead to the development of GC resistance [59]. 
In paper 4 the habilitant and her research group investigated the impact of occurring genetic 
polymorphisms within the NR3C1 gene encoding for Glucocorticoid receptor α on the therapy 
efficacy of steroids in IBD patients. The research group comprehensively described for the first 
time all occurring genetic variants and arising haplotypes within the whole exome of NR3C1. For 
this purpose, all exonic regions and flanking intronic regions of NR3C1 were sequenced in IBD 
patients, who had formerly responded to a GC treatment () and in GC non-responders () suffering 
from IBD. The habilitant detected the occurring genetic variants using the blasting algorithm 
(www.ncbi.gov), bioinformatically predicted the occurring haplotypes of the GRα gene using the 
software tool Haploview and investigated them in context to therapy outcome with glucocorticoids. 
The research group could show that GRα appears to be strongly conserved and only rarely 
polymorphically expressed. Genetic variants within NR3C1 appeared not to be differentially 
distributed within GC responders and non-responders, thus, providing evidence that a polymorphic 
expression of GRα does not serve as a susceptibility marker for a GC associated therapy failure in 
Crohn’s Disease or Ulcerative Colitis.  
 
 3.5 The impact of PPARγ genetic variants on IBD susceptibility and IBD disease course 
(Paper 5) 
Current evidence suggests that PPARγ, a nuclear receptor and key regulator of genes involved in 
lipid metabolism and insulin sensitization plays an important role in the regulation of inflammatory 
processes. By modulating the expression of important transcription factors and kinases involved in 
inflammatory signalling cascades (e.g. NF-κB, c-Jun, and c-Fos), PPARγ is able to inhibit the 
mucosal production of important proinflammatory cytokines (e.g. interleukin 1β (IL-1β) and tumor 
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necrosis factor-α (TNFα)) and to downregulate the expression of various adhesion molecules [60] 
[61; 62] By it, PPARγ is able to efficiently reduce the severity of intestinal inflammation by 
suppressing excessive immunoinflammatory responses e.g. in the gastrointestinal tract, as 
demonstrated in mice experiments [63; 64].  Because of its apparent significant impact on the 
regulation of proinflammatory processes in the colon, we hypothesized that PPARγ could be a 
putative susceptibility gene for the development of IBD. In paper 5, the habilitant and her research 
team comprehensively described for the first time all occurring genetic variants and arising 
haplotypes in the whole exome of the PPARγ encoding gene NR1C3. This was accomplished by 
sequencing all exonic and the flanking intronic regions of the most abundantly expressed splice 
variant PPARγ2 in a reasonably large IBD Swiss case and non-IBD control group (140 UC, 144 CD 
patients and 194 healthy individuals, respectively). The sequencing results were blasted against 
the reference sequence and the frequencies of the occurring NR1C3 gene variants were 
determined in each group. Haplotype and diplotype frequencies were bioinformatically predicted 
and compared in case and control group using the software tool FAMHAP. Interestingly, the 
PPARγ gene appeared to be sparsely polymorphically expressed. Only two genetic variants that 
were earlier described in the literature appeared to occur in an allelic frequency > 1%. None of the 
genetic variants or the arising haplo- and diplotypes were associated with a modulated risk for IBD 
development. Neither were the genetic variants associated with a modulated IBD course, as tested 
by stratification according to clinical disease activity, fistula state or the occurrence of 
extraintestinal manifestations.  Thus, the performed study proved that a polymorphic expression of 
PPARγ does not serve as a susceptibility marker for the development of IBD or disease activity.   
 
4. Value of the presented work and future perspectives  
The studies presented here have yielded important insights into the involvement of transcriptional 
regulatory pathways and genetic variants in drug safety and efficacy and in the pathogenesis of 
IBD. Specifically, the project results have provided mechanistic explanations of how drug side 
effects by a polymorphic expression of drug transporters may occur or how drug-drug interactions 
may develop, giving the possibility to significantly lower the risk of severe side drug side effects 
based on the gained knowledge.  Additional  the overall SNP composition of two important nuclear 
receptors were extensively studied, which is potentially not only of value with regard to the the 
investigations made in the context of IBD pathogenesis and treatment but may also be of 
relevance for other diseases of chronic inflammatory origin.   
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Background to the presented work  
Pharmacogenetics. Many genetic variants, e.g. in genes encoding for cytochrome P450 enzymes 
or for hepatic transporters have been shown to essentially influence the individual susceptibility for 
drug side effects. The research field of pharmacogenetics investigates to which extent genetic 
polymorphisms modulate patients’ individual responses to medical treatments.  
OATP1B1 and CYP2C19. The hepatically expressed transport protein OATP1B1 is involved in the 
active uptake of a variety of different drugs from the portal blood into the liver, including e.g. the 
HMG-CoA reductase inhibitor pravastatin. Especially three non-synonymous SNPs, the genetic 
variants SLCO1B1*1b, *3 and *5 occur in a high frequency within the SLCO1B1 gene and have 
been shown in vitro to modulate the OATP1B1 drug transport efficacy. The Cytochrome P450 
family member CYP2C19 is as well mainly expressed in the liver and metabolizes about 5% of 
currently used therapeutics, including proton pump inhibitors. The coding gene CYP2C19 is highly 
polymorphically expressed with high impact on drug safety and efficacy. While CYP2C19 slow 
metabolizers (carriers of the SNP *2 or *3) have been shown to be at higher risk for thrombotic 
events under treatment with the anticoagulative acting prodrug clopidogrel, ultrafast metabolizers 
(genetic variant *17) appear to be at lower risk for thrombotic events under clopidogrel.  
The transcription factor family of Nuclear Receptors: Nuclear receptors are involved in the 
regulation of a wide range of metabolic pathways via ligand-dependent activation and induction of 
transcription changes of different genes. NRs typically recognize a pair of 5 to 6 bp long DNA 
sequences, which are separated by a spacer of 1 to 6 bases of length. Based on the type of ligand 
specificity NRs are devided into three subfamilies, including classic endocrine receptors that bind 
steroid and thyroid hormones and vitamine A and D derivates, orphan receptors, for which the 
ligands have not been identified yet and receptors, which bind dietary lipids and their metabolites.   
Molecular biological mechanisms behind the pathogenesis of IBD: The inflammatory bowel 
diseases (IBD) Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disease 
of the gastrointestinal tract, which are associated with a strong loss in life quality, work inability, 
repeated bowel surgeries and a putatively elevated risk for the development of colorectal cancer. 
Curative therapy strategies for IBD do not yet exist. Not yet exactly elucidated, the pathogenesis of 
IBD is thought to be of multifactorial genesis, whereby environmental, microbial, immune and 
genetic factors seem to play a key role. Current therapy approaches in IBD focus on a control of 
ongoing autoinflammatory processes within the bowel endothelium by using drugs that inhibit the 
production or the action of cytokines, which includes the use of e.g. steroids, 5-amino salicylic acid 
(5-ASA), immunosuppressants (azathioprine) or biologicals (Anti-TNFα-antibodies (-abs)).  
Discussion of the selected publications 
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics 
(Paper 1): In this study it was investigated to which extent the genetic variants SLCO1B1*1b 
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(rs2306283, c.388A>G) and *5 (rs4149056, c.521T>C) of the gene encoding for the liver uptake 
transporter OATP1B1 influence the pharmacokinetics of pravastatin in vivo. The trial included 30 
healthy white individuals, either carriers of the alleles SLCO1B1*1b, *5 or homozygous carriers of 
the wild type allele, who were treated with a single dose of 40mg pravastatin. The polymorphism 
c.521T>C appeared to be associated with a significant lower OATP1B1 uptake transport capacity 
for pravastatin into the liver, as demonstrated by significantly higher pravastatin plasma 
concentrations (AUC0-6h) in SLCO1B1*5 carriers compared to wild type carriers. In contrast, 
carriers of SLCO1B1*1b showed lower pravastatin levels compared to wild type carriers, as 
demonstrated in lower pravastatin concentrations in 24h-urine. This was the first study, which 
proved a significant impact of OATP1B1 variants on an HMG-CoA-inhibitor in vivo.   
Regulation of CYP2C19 expression by estrogen receptor alpha. Implications for estrogen 
dependent inhibition of drug metabolism (Paper 2): Beside a polymorphic expression, the activity of 
the hepatic drug metabolizing enzyme CYP2C19 is known to be modulated by different drugs, 
leading to important drug-drug interactions. The intake of oral contraceptives (OCs) inhibits the 
metabolic efficacy of CYP2C19 in vivo. To elucidate the mechanism behind this inhibitory effect, 
the habilitant investigated the ability of estradiol derivatives and partial estrogen antagonists to 
modulate CYP2C19 gene expression via an Estrogen Receptor (ER) dependent regulatory 
pathway. Initially, several putative ER binding motifs within the CYP2C19 gene promoter were 
detected in silico. Using important in vitro techniques, such as cell line based co-transfection 
techniques and luciferase gene reporter assays, electromobility shift assays and ChIP and 
TaqMan® analysis, it could be shown that estradiol derivates are able to significantly inhibit 
CYP2C19 gene expression via a functionally active ERα – binding half site within the first 200bp of 
the CYP2C19 promoter, an effect, which was reversible by the partial antagonist 4-OH-tamoxifen. 
The detected mechanism has putatively model character for a general principle, how estradiol 
derivatives might unfold their inhibitory potential on other members of the CYP enzyme family.  
Association of a common vitamin D-binding protein (DBP) polymorphism with inflammatory bowel 
disease (Paper 3): Vitamin D is a key regulator in calcium and phosphate homeostasis. Its effect is 
mediated by the Vitamin D receptor, which binds vitamin D and subsequently modulates gene 
expression of different target genes. Vitamine D binding protein (DBP) is localized in human 
plasma, where it mediates 85% vitamin D transport to its target tissues. Furthermore, DBP is able 
to directly activate macrophages and to stimulate chemotaxis of neutrophil granulocytes. 
Interestingly, there is a strong correlation between the prevalence of IBD and the occurrence of 
vitamine D deficiency In Paper 3 the habilitant investigated to which extent a polymorphic 
expression of the human Vitamin D-binding protein (DBP) has an impact on IBD development, 
investigating the prevalence of the two DBP isoform determining common genetic variants rs7041 
and rs4588 in 636 IBD patients and 248 non-IBD controls. The polymorphism rs4588, which has 
earlier been shown to  be less effective in vitamin D3 binding, was significantly less frequent in the 
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IBD patient group Further studies have to elucidate in which way the enhanced rs4588 triggered 
release of vitamin D from DBP exerts the apparent protective effect observed in this study.  
Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients 
(Paper 4): Glucocorticoids (GCs) are efficient drugs in the treatment of inflammatory bowel 
diseases, exerting a potent inhibition of T cell activation and cytokine secretion via a modulation of 
glucocorticoid receptor α (GRα) dependent signalling pathways. A major problem in IBD treatment 
is that 20% of patients develop GC resistance within one year of treatment. In paper 4 the 
habilitant studied the impact of genetic polymorphisms within the Glucocorticoid receptor α gene 
NR3C1 on the therapy outcome in IBD patients treated with steroids. All occurring genetic variants 
and arising haplotypes within NR3C1 were determined by whole exome sequencing and 
subsequent haplotype analysis in IBD patients, who had formerly responded to a GC treatment () 
and in GC non-responders (). Interestingly, GRα appeared to be only rarely polymorphically 
expressed. Genetic variants within NR3C1 were not differentially distributed between GC 
responders and non-responders, thus, providing evidence that GRα polymorphisms do not serve 
as a susceptibility marker for a GC associated therapy failure in IBD.  
The impact of PPARγ genetic variants on IBD susceptibility and IBD disease course (Paper 5): 
PPARγ belongs to the nuclear receptor family and is key regulator of inflammatory processes by 
modulating the expression of transcription factors and kinases involved in the inhibition of 
proinflammatory signalling cascades. To investigate whether a polymorphic expression of PPARγ 
could serve as susceptibility marker for IBD the habilitant comprehensively determined the genetic 
variants and arising haplotypes within the whole exome of the PPARγ encoding gene NR1C3 by 
sequencing all exonic and the flanking intronic regions of the most abundantly expressed splice 
variant PPARγ2 and predicting bioinformatically the occurring haplotypes in a reasonably large IBD 
case and non-IBD control group (294 IBD patients and 194 healthy individuals). Interestingly, the 
PPARγ gene appeared to be sparsely polymorphically expressed. Only two genetic variants 
occurred in an allelic frequency > 1%. Neither the detected polymorphisms nor the predicted 
haplotypes were associated with a modulated risk for IBD development or disease course, thus 
proving, that PPARγ polymorphisms do not modulate the individual risk for IBD.    
Value of the presented work  
The studies presented here have yielded important insights into the involvement of transcriptional 
regulatory pathways and genetic variants in drug safety and efficacy and in the pathogenesis of 
IBD. Specifically, the project results have provided important mechanistic explanations of how drug 
side effects by a polymorphic expression of drug transporters may occur or how drug-drug 
interactions may develop.   
